This Week in The Roadhouse Pharmacy
THE ROADHOUSE PHARMACY: There’s a great deal of interest in the Bio-tech sector at the moment, so we have opened our own Pharmacy to keep our readers up to speed.
Patrys completes successful clinical trial
Patrys Limited (ASX: PAB) has received final results from a Phase I/IIa, open-label study of PAT-SM6 in patients with refractory or relapsed multiple myeloma (MM). READ MORE…
Regeneus osteoarthritis treatment shows continued improvement
Regenerative medicine company, Regeneus (ASX: RGS) announced further results from its ethics approved joint registry used to track the safety and effectiveness of the company’s innovative cell therapy, HiQCell®, in the treatment of osteoarthritis. READ MORE…
Bone Medical ties up BN006 research collaboration
Bone Medical Ltd (ASX: BNE) has entered into a research agreement with William Harvey Research Limited (WHRL), to further study the company’s anti-inflammatory molecule for rheumatoid arthritis (RA), BN006, and support its progress towards clinical studies in man. READ MORE…
Imugene allowed Israel patent for cancer vaccine
Australian biopharmaceutical company Imugene Limited (ASX: IMU) has been issued an Intention to Grant notice from the Israeli Patent Office for the company’s proprietary cancer vaccine HER-Vaxx (Patent no. IL 194162, 2027expiry). READ MORE…
Patrys advances PAT-LM1 to clinical development
Clinical stage biotechnology company Patrys Limited (ASX: PAB) has released an update on the development program for the company’s anti-cancer product, PAT-LM1. READ MORE…